At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BLRX BioLine Rx
Not Yet Opened 07-29 16:00:00 EDT
4.13
-0.03
-0.72%
盘后4.13
+0.000.00%
16:10 EDT
High4.31
Low4.03
Vol23.04K
Open4.31
D1 Closing4.16
Amplitude6.73%
Mkt Cap15.37M
Tradable Cap14.63M
Total Shares3.72M
T/O94.50K
T/O Rate0.65%
Tradable Shares3.54M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
BioLine RX Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.